PE20221758A1 - Composiciones y metodos para la induccion de una respuesta inmune - Google Patents

Composiciones y metodos para la induccion de una respuesta inmune

Info

Publication number
PE20221758A1
PE20221758A1 PE2022001921A PE2022001921A PE20221758A1 PE 20221758 A1 PE20221758 A1 PE 20221758A1 PE 2022001921 A PE2022001921 A PE 2022001921A PE 2022001921 A PE2022001921 A PE 2022001921A PE 20221758 A1 PE20221758 A1 PE 20221758A1
Authority
PE
Peru
Prior art keywords
induction
methods
compositions
immune response
viral vector
Prior art date
Application number
PE2022001921A
Other languages
English (en)
Inventor
Sarah C Gilbert
Teresa Lambe
Sarah Sebastian
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003670.3A external-priority patent/GB202003670D0/en
Priority claimed from GBGB2006608.0A external-priority patent/GB202006608D0/en
Priority claimed from GBGB2007062.9A external-priority patent/GB202007062D0/en
Priority claimed from GBGB2009239.1A external-priority patent/GB202009239D0/en
Priority claimed from GBGB2010569.8A external-priority patent/GB202010569D0/en
Priority claimed from GBGB2016922.3A external-priority patent/GB202016922D0/en
Priority claimed from GBGB2017284.7A external-priority patent/GB202017284D0/en
Priority claimed from GBGB2017677.2A external-priority patent/GB202017677D0/en
Priority claimed from GBGB2018410.7A external-priority patent/GB202018410D0/en
Priority claimed from GBGB2018718.3A external-priority patent/GB202018718D0/en
Priority claimed from GBGB2100034.4A external-priority patent/GB202100034D0/en
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of PE20221758A1 publication Critical patent/PE20221758A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a una composicion que comprende un vector viral, comprendiendo el vector viral un acido nucleico que tiene una secuencia de polinucleotidos que codifica para la proteina de pico del coronavirus SARS-CoV2, caracterizada porque dicho vector viral es un vector basado en adenovirus. La invencion tambien se refiere a los usos de una composicion de ese tipo y metodos de tratamiento
PE2022001921A 2020-03-13 2021-03-11 Composiciones y metodos para la induccion de una respuesta inmune PE20221758A1 (es)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GBGB2003670.3A GB202003670D0 (en) 2020-03-13 2020-03-13 Compositions and methods for inducing an immune response
GBGB2006608.0A GB202006608D0 (en) 2020-05-05 2020-05-05 Compositions and methods for inducing an immune response
GBGB2007062.9A GB202007062D0 (en) 2020-05-13 2020-05-13 Compositions and methods for inducing an immune response
GBGB2009239.1A GB202009239D0 (en) 2020-06-17 2020-06-17 Compositions and methods for inducing an immune response
GBGB2010569.8A GB202010569D0 (en) 2020-07-09 2020-07-09 Compositions and methods for inducing an immune response
GBGB2016922.3A GB202016922D0 (en) 2020-10-26 2020-10-26 Compositions and methods for inducing an immune response
GBGB2017284.7A GB202017284D0 (en) 2020-10-30 2020-10-30 Compositions and methods for inducing an immune response
GBGB2017677.2A GB202017677D0 (en) 2020-11-09 2020-11-09 Compositions and methods for inducing an immune response
GBGB2018410.7A GB202018410D0 (en) 2020-11-23 2020-11-23 Compositions and Methods for Inducing an Immune Response
GBGB2018718.3A GB202018718D0 (en) 2020-11-27 2020-11-27 Compositions and methods for inducing an immune response
GBGB2100034.4A GB202100034D0 (en) 2021-01-04 2021-01-04 Compositions and methods for inducing an immune response
PCT/GB2021/050602 WO2021181100A1 (en) 2020-03-13 2021-03-11 Compositions and methods for inducing an immune response

Publications (1)

Publication Number Publication Date
PE20221758A1 true PE20221758A1 (es) 2022-11-11

Family

ID=75108658

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001921A PE20221758A1 (es) 2020-03-13 2021-03-11 Composiciones y metodos para la induccion de una respuesta inmune

Country Status (19)

Country Link
US (1) US20230285532A1 (es)
EP (1) EP4117723A1 (es)
JP (1) JP2023517286A (es)
KR (1) KR20220152248A (es)
CN (1) CN115720522A (es)
AU (1) AU2021235248A1 (es)
BR (1) BR112022016580A2 (es)
CA (1) CA3171939A1 (es)
CL (1) CL2022002420A1 (es)
CO (1) CO2022011811A2 (es)
CR (1) CR20220501A (es)
DO (1) DOP2022000184A (es)
EC (1) ECSP22076973A (es)
IL (1) IL295630A (es)
MX (1) MX2022011394A (es)
PE (1) PE20221758A1 (es)
TW (1) TW202200198A (es)
UY (1) UY39131A (es)
WO (1) WO2021181100A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113521268A (zh) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
WO2023026182A1 (en) * 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023135439A1 (en) * 2022-01-17 2023-07-20 Institut Pasteur Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine
GB202201765D0 (en) * 2022-02-11 2022-03-30 Virax Biolabs Uk Ltd Methods
GB202201768D0 (en) * 2022-02-11 2022-03-30 Virax Biolabs Uk Ltd Peptides
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
GB201708444D0 (en) * 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Compositions and methods for inducing an immune response

Also Published As

Publication number Publication date
AU2021235248A1 (en) 2022-09-01
JP2023517286A (ja) 2023-04-25
ECSP22076973A (es) 2022-12-30
KR20220152248A (ko) 2022-11-15
CR20220501A (es) 2023-01-23
CN115720522A (zh) 2023-02-28
EP4117723A1 (en) 2023-01-18
IL295630A (en) 2022-10-01
DOP2022000184A (es) 2022-10-16
CO2022011811A2 (es) 2022-08-30
CL2022002420A1 (es) 2023-04-28
CA3171939A1 (en) 2021-09-16
WO2021181100A1 (en) 2021-09-16
MX2022011394A (es) 2022-10-13
TW202200198A (zh) 2022-01-01
US20230285532A1 (en) 2023-09-14
UY39131A (es) 2021-09-30
BR112022016580A2 (pt) 2022-11-16

Similar Documents

Publication Publication Date Title
PE20221758A1 (es) Composiciones y metodos para la induccion de una respuesta inmune
CL2020002755A1 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
EA201890999A1 (ru) Вакцина против вируса простого герпеса
CL2019000729A1 (es) Proteínas de unión recombinantes y sus usos.
DOP2018000245A (es) Proteinas de fusion gdf15 y usos de estas
CL2018001107A1 (es) Variantes del factor viii cpg reducido, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasis.
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
EA201992882A1 (ru) САМОРЕГУЛИРУЕМЫЕ ВЕКТОРЫ НА ОСНОВЕ AAV ДЛЯ БЕЗОПАСНОЙ ЭКСПРЕССИИ MeCP2 ПРИ СИНДРОМЕ PETTA
AR105470A1 (es) Métodos para inducir una respuesta inmune
CL2019000704A1 (es) Vectores de adenovirus canino.
AR102006A1 (es) Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
CL2017002334A1 (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular
EA202090049A1 (ru) Поксвирусные векторы, кодирующие антигены вич, и способы их применения
MX2017010908A (es) Vacuna bivalente contra el virus de gripe porcina.
EA202092828A1 (ru) Антигенный вариант вируса varicella zoster и его применение
BR112018015696A2 (pt) composições e métodos para gerar uma resposta imune para um flavivírus
CO2022004470A2 (es) Vectores de herpesvirus de los pavos recombinante que expresan antígenos de patógenos aviares y usos de estos
MX2017012389A (es) Vacuna del virus de la parotiditis recombinante jeryl lynn2.
AR122393A1 (es) Composiciones y métodos para la inducción de una respuesta inmune
EA202092335A1 (ru) Композиции на основе эренумаба и пути их применения
CL2023000146A1 (es) Excipientes reductores de la viscosidad y combinaciones de los mismos para formulaciones proteicas altamente concentradas
EA202091177A1 (ru) Композиции и схема иммунизации против гепатита b
CO2018007442A2 (es) Vacunas contra el cáncer